Drug budget and patent improvements on US industry's wish list for Taiwan
This article was originally published in Scrip
Executive Summary
The US research-based pharma industry continues to harbour concerns over drug reimbursement, intellectual property and regulatory policies in Taiwan that it warns risk affecting patient access to new therapies and incentives for foreign investment.